 |
 | |||||
| ||||||
- Augusta Resource Corporation Announced The Retirement Of Senior Vice President ... - Galaxy Stocks
18 May 2012 Augusta Resource Corporation Announced The Retirement Of Senior Vice President ...
Galaxy Stocks
BioTime, Inc. (NYSE Amex:BTX) announced recently the publication of a scientific paper demonstrating the effectiveness of HyStem®-C in the transplantation of heart muscle-derived cells in an animal model of heart disease.und weitere » - HyStem®-C Demonstrated Effective when Formulated with Human Heart Cells and ... - BiotechStockTrader.com
16 May 2012 HyStem®-C Demonstrated Effective when Formulated with Human Heart Cells and ...
BiotechStockTrader.com
BioTime, Inc. (NYSE MKT: BTX) announced today the publication of a scientific paper demonstrating the effectiveness of HyStem ® -C in the transplantation of heart muscle-derived cells in an animal model of heart disease.- BIOTIME, INC. : HyStem(R)-C Demonstrated Effective when Formulated with Human ... - 4-traders
14 May 2012 BIOTIME, INC. : HyStem(R)-C Demonstrated Effective when Formulated with Human ...
4-traders
BioTime, Inc. : HyStem(R)-C Demonstrated Effective when Formulated with Human Heart Cells and Transplanted in an Animal Model of Heart Disease ALAMEDA, Calif., May 14, 2012 (BUSINESS WIRE) --BioTime, Inc. (NYSE MKT: BTX) announced today the publication ...
HyStem(R)-C Demonstrated Effective when Formulated with Human Heart Cells and ...MarketWatch (press release)
HyStem®-C Demonstrated Effective when Formulated with Human Heart Cells and ...EON: Enhanced Online News (press release) Alle 9 Artikel » - BioTime (NYSE AMEX: BTX) Q1/12 Results and Highlights - Proactive Investors USA & Canada
11 May 2012 BioTime (NYSE AMEX: BTX) Q1/12 Results and Highlights
Proactive Investors USA & Canada
BTX and its subsidiary LifeMap Sciences, Inc. announced a definitive agreement to acquire XenneX, Inc. through a merger of XenneX into LifeMap Sciences. XenneX holds the exclusive, worldwide licenses to market GeneCards^® and PanDaTox.und weitere » - BioTime Announces First Quarter 2012 Financial Results and Recent Corporate ... - Reuters
11 May 2012 BioTime Announces First Quarter 2012 Financial Results and Recent Corporate ...
Reuters
Alameda, Calif., May 10, 2012 - BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the first quarter ended March 31, ...und weitere » - BioTime: Backed By Dubious Stock Promoters - Seeking Alpha
26 Apr 2012 BioTime: Backed By Dubious Stock Promoters
Seeking Alpha
In our previous article, we discussed how BioTime, Inc. (BTX) has used press releases, particularly regarding the creation and acquisition of numerous subsidiaries, to boost the company's share price. In addition to its in-house promotional efforts, ...- Keryx Announces Positive Top-Line Results from Phase 3 Study; Medgenics Files ... - Proactive Investors USA & Canada
24 Apr 2012 Keryx Announces Positive Top-Line Results from Phase 3 Study; Medgenics Files ...
Proactive Investors USA & Canada
BioTime, Inc. (NYSE Amex: BTX) announced today that David Warshawsky, Ph.D., CEO of BioTime's subsidiary LifeMap Sciences, Inc. will provide and update on product development at an investor meeting in New York City today. Biovest International, Inc.und weitere » - BioTime's Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development - SunHerald.com
23 Apr 2012 BioTime's Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development
SunHerald.com
BioTime, Inc. (NYSE Amex: BTX) announced today that David Warshawsky, Ph.D., CEO of BioTime's subsidiary LifeMap Sciences, Inc. will provide and update on product development at an investor meeting in New York City today. Dr. Warshawsky will describe ...und weitere » - BioTime's Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development - MarketWatch (press release)
23 Apr 2012 BioTime's Subsidiary LifeMap Sciences, Inc. Presents Update on Product Development
MarketWatch (press release)
ALAMEDA, Calif., Apr 23, 2012 (BUSINESS WIRE) -- BioTime, Inc. (ASE:BTX) announced today that David Warshawsky, Ph.D., CEO of BioTime's subsidiary LifeMap Sciences, Inc. will provide and update on product development at an investor meeting in New York ...
BIOTIME, INC. : BioTime's Subsidiary Cell Cure Neurosciences, Ltd. Provides ...4-traders
BioTime and its Subsidiary OrthoCyte Corporation Provides Update on ...SunHerald.com
BioTime's Subsidiary ReCyte Therapeutics, Inc. Provides Update on Preclinical ...EON: Enhanced Online News (press release) PharmiWeb.com (press release) -Benzinga Alle 49 Artikel » - BioTime and its Subsidiary OrthoCyte Corporation Provides Update on ... - Benzinga
23 Apr 2012 BioTime and its Subsidiary OrthoCyte Corporation Provides Update on ...
Benzinga
By Allie Wickman BioTime, Inc. (NYSE: BTX) announced today that BioTime's CEO Michael West, Ph.D. will provide and update the development of OTX-CP07 by BioTime's subsidiary OrthoCyte Corporation at an investor meeting in New York City.und weitere »
- Facebook im Sinkflug
21 May 2012 - Erster Kurs zu Wochenstart bei 36,53 Dollar
- Von Chelsea lernen: Die Defensive ist Trumpf
21 May 2012 - Verunsicherung bleibt - Deutschland leiht sich Geld bereits für 0,0264% auf ein Jahr. Spaniens Rezession prolongiert
- Formel 1 geht in Singapur an die Börse
21 May 2012 - Kreise: IPO-Ziel sind 3 Milliarden US-Dollar
- Wiener Börse startet freundlich
21 May 2012 - Zwölf Aktien legen zu, sieben im Minus
- Frauenthal verliert im Q1 den gesamten Gewinn
21 May 2012 - Ergebnis fällt um 3,5 Mio. Euro auf plus/minus Null
- Wenig Hoffnung auf Erholung an den Märkten
20 May 2012 - Technisch sind die Indizes angeschlagen
- Böhmdorfer zu Immobiliendeal im U-Ausschuss
20 May 2012 - Ex-Telekom-Chef Sundt zu Nordbergstraße geladen
- Rückkehr zur Drachme wäre "ganz bestimmt das pure Chaos"
20 May 2012 - RZB-Chef Rothensteiner warnt vor Euro-Abschied Griechenlands
- Immer mehr Notkredite für Banken in Krisenländern
20 May 2012 - Zentralbanken borgten Banken in Griechenland, Irland, Spanien und Zypern im März mehr als 120 Mrd. Euro
- DAX: Auch die Analysten malen schwarz
20 May 2012 - Keine nachhaltige Erholung des Dax in Sicht - Lage in Spanien spitzt sich zu - Spekulationen um Euro-Austritt Griechenlands reissen nicht ab
- "Die Grenze der vertretbaren Griechenland-Risiken bei den Notenbanken der Eurozone erreicht"
20 May 2012 - Bundebank-Präsident: Finanzierungshilfen der EZB nur vorübergehend
- Katerstimmung an der Wall Street nach Facebook-Flop
20 May 2012 - Experten: Kurzfristige Rally möglich, aber allgemeiner Trend weist nach unten - EU-Schuldenkrise als Stimmungstöter - Daten über US-Immobilienmarkt am Dienstag
- Erste Group zu Andritz, Do&Co, Mayr-Melnhof, Post, RHI und Semperit
20 May 2012 - Aktuelle Empfehlungen
- 'Von der Tagesaktualität nicht verrückt machen lassen'
20 May 2012 - Quo Vadis, ATX? Fondsmanager Wögerbauer antwortet
- U-Ausschuss lädt diesmal Grasser und Böhmdorfer als Zeugen
19 May 2012 - Beweisthema Buwog wird vorerst abgeschlossen
- Verhaltenes Börsendebüt von Facebook
19 May 2012 - Schlusskurs nur hauchdünn über Ausgabepreis - Kurse anderer Internetfirmen nach unten gezogen - Klage über 15 Milliarden Dollar
- Für Gesprächsstoff ist in Wien gesorgt
19 May 2012 - Termine der Woche
- Merkel schlägt Griechenland Euro-Referendum vor - Deutschland dementiert
18 May 2012 - Im Gespräch mit Staatspräsident Papoulias
- Merkel schlägt Griechenland Euro-Referendum vor
18 May 2012 - Im Gespräch mit Staatspräsident Papoulias
- Facebook-Börsendebüt mit Schrecksekunde und Nasdaq-Panne
18 May 2012 - Das Vermögen von Gründer und Chef Zuckerberg schwankt mit jeder Dollar-Marke beim Aktienkurs gleich um 500 Millionen Dollar